An Early Phase 1 interventional study of Cevimeline in Dry Mouth, sponsored by Roxane Laboratories. Completed at 1 site in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-01-23.
Sponsored by Roxane Laboratories · Early Phase 1, Interventional, and Treatment
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fed conditions
254 studies on the registry are indexed under Xerostomia; 47 are open to participants now.
This study's enrollment of 27 is below the median of 42 across 216 interventional studies indexed under Xerostomia.
Browse Xerostomia studies →Roxane Laboratories is the lead sponsor of 98 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Single dose 30 mg cevimeline capsule, then single dose 30 mg Evoxac capsule (after washout period)
Drug: Cevimeline
Single dose 30 mg Evoxac capsule, then single dose 30 mg cevimeline capsule (after washout period)
Drug: Cevimeline
Also known as: Evoxac
bioequivalence determined by statistical comparison Cmax
Time frame: 33 Days
This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Roxane Laboratories